University of Oxford Confidence in Concept Scheme – Round 6

Lead Research Organisation: University of Oxford

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description American Thoracic Society technical statement on pre-school multi-breath washout testing - Grant Ritchie Project
Geographic Reach North America 
Policy Influence Type Citation in other policy documents
URL https://www.ncbi.nlm.nih.gov/pubmed/29493315
 
Description CML diagnostic service in Muhimbili National Hospital funded by Tanzanian Government and led to change in practice - Anna Schuh Project
Geographic Reach Africa 
Policy Influence Type Influenced training of practitioners or researchers
Impact CML diagnostic service in Muhimbili National Hospital (Dar Es Salaam) is now funded by the Tanzanian Government and had led to change in practice as it allows free access to highly effective drugs
 
Description 3 year research agreement to develop Universal Influenza Vaccine and surrounding research portfolio - Sunetra Gupta Project
Amount £420,000 (GBP)
Organisation Blue Water Vaccines Inc. 
Sector Private
Country United States
Start  
 
Description Acute Leukaemia Diagnosis: Transfer sequencing technology for leukaemia diagnosis
Amount £260,000 (GBP)
Organisation Business for Social Responsibility 
Sector Charity/Non Profit
Country United States
Start 01/2021 
End 01/2023
 
Description AfOx Visiting Fellowship for President of the Tanzanian Society of Human Genetics - Anna Schuh Project
Amount £6,000 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start  
 
Description Brain Delivery Of RNA Based Therapy Using Antibody And Bispecific Antibody-RNA Conjugates (Arcs) - Suzan Hammond Project
Amount £918,141 (GBP)
Organisation RT Ventures 
Sector Private
Country United Kingdom
Start  
 
Description Global Haematology Scholarship: Visiting fellowship to learn Nanopore technology and attend Early Phase Clinical Trial Unit and haematology service in Oxford - Anna Schuh Project
Amount £6,000 (GBP)
Organisation British Society for Haematology 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Improving diagnosis of CLL - Anna Schuh. To pilot Global Health Research Initiative benefitting patients with CLL
Amount £125,000 (GBP)
Organisation National Institutes of Health (NIH) 
Department National Cancer Institute (NCI)
Sector Public
Country United States
Start 01/2021 
End 01/2023
 
Description MLSTF Enhanced Internal - Anna Schuh Plus In-kind support from Nanopore
Amount £50,700 (GBP)
Organisation Oxford Nanopore Technologies 
Sector Private
Country United Kingdom
Start 07/2019 
End 08/2020
 
Description MLSTF: "To expand test repertoire to Nanopore technology and leukaemia indications" - Anna Schuh Project
Amount £37,400 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start  
 
Description Novel antibody-oligonucleotide drug conjugates target the CNS to treat neuromuscular disease
Amount £225,000 (GBP)
Funding ID 19GRO-PG36-0294 
Organisation Muscular Dystrophy UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 12/2022
 
Description Phase I clinical trial in collaboration with Oxford Vaccine Group - Sunetra Gupta Project
Amount £590,000 (GBP)
Organisation Blue Water Vaccines Inc. 
Sector Private
Country United States
Start  
 
Description Research and Innovation for Global Health Transformation (RIGHT): "Evaluation and Transfer of mobile whole slide tissue scanners...for improved outcomes of children and young adults with EBV-driven lymphoma" - Anna Schuh Project
Amount £4,300,000 (GBP)
Funding ID NIHR200133 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description SIDA Tanzania: Frequency of TP53 mutation in patients with chronic lymphocytic leukemia at Muhimbili National Hospital - Anna Schuh Project
Amount £10,000 (GBP)
Organisation Swedish International Development Cooperation Agency 
Sector Public
Country Global
Start  
 
Description The Idealised Lung Clearance Index: tuning in to the silent years of cystic fibrosis - Grant Ritchie Project
Amount £461,345 (GBP)
Funding ID EP/T001186/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start  
 
Description The idealised LCI (i-LCI): tuning in on the 'silent years' of paediatric CF - Grant Ritchie Project
Amount £98,594 (GBP)
Organisation Cystic Fibrosis Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Title Establish a pipeline for identifying highly immunogenic and potent vaccine targets - Sunetra Gupta project 
Description Establish a pipeline for identifying highly immunogenic and potent vaccine targets 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? No  
Impact Potential for identifying other highly immunogenic and potent vaccine targets 
 
Title Produce an immunogenic virus-like particle that can be synthesised cheaply in E.coli or used in a viral vector - Sunetra Gupta Project 
Description Production of an immunogenic virus-like particle that can be synthesised cheaply in E.coli or used in a viral vector 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? No  
Impact Identification of other vaccine targets for other pathogens. 
 
Description Acute Leukaemia Diagnostics: Illumina - Anna Schuh 
Organisation Illumina Inc.
Department Illumina
Country United Kingdom 
Sector Private 
PI Contribution Expansion of our test reservoir. Building of our DNA Sequencing laboratory at MUHAS
Collaborator Contribution Transfer sequencing technology for leukaemia diagnosis
Impact n/a
Start Year 2021
 
Description AstraZeneca partnership to explore the use of anti-TfR-ASOs for Huntington's Disease - Suzan Hammond project 
Organisation AstraZeneca
Department Astra Zeneca
Country United States 
Sector Private 
PI Contribution Joint application for research assistant to explore the use of anti-TfR-ASOs for Huntington's Disease
Collaborator Contribution Joint application for research assistant to explore the use of anti-TfR-ASOs for Huntington's Disease
Impact Joint application for post doctoral researcher will yield further research outputs
Start Year 2019
 
Description Brain delivery of RNA based therapy using Antibody and bispecific antibody-RNA conjugates (ARCs) - Suzan Hammond 
Organisation RT Ventures
Country United Kingdom 
Sector Private 
PI Contribution The aim of this proposal is to develop monoclonal and bispecfic antibodies that can target discovery of oligonucleotide therapy to specific neuronal types in the brain and spinal cord for therapeutic delivery of RNA based therapies for neurodegenerative diseases
Collaborator Contribution the venture fund group RT Ventures has provided funding for 18 months to accelerate the program into a potential spin-out. Licensing agreements are still in negotiation.
Impact Not quite yet.
Start Year 2020
 
Description Novel Antibody Oligonucleotide drug conjugates target the CNS to treat neuromuscular disease. Suzan Hammond 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Funding has been provided by Muscular Dystrophy UK. The aim of this proposal is to develop novel mAb-ASO and BsAb-ASOs for treatment of spinal muscular atrophy and create a platform of Ab selection that we can use to generate new Ab-ASO drug compounds for multiple neuromuscular diseases
Collaborator Contribution Partnered up with AstraZeneca to explore the use of anti-TfR-ASOs for Huntington's Disease through an application for a postdoctoral researcher to work between AZ and myself.
Impact n/a
Start Year 2020
 
Title AN EXTRACELLULAR VESICLE 
Description The present invention relates to compositions for the delivery of molecules such as a peptide, a nucleic acid and/or a small molecule drug. In particular, the present invention relates to an extracellular vesicle (EV) loaded with a peptide, a nucleic acid and/or a small molecule drug, along with methods of producing said EV. 
IP Reference WO2021084274 
Protection Patent granted
Year Protection Granted 2021
Licensed No
Impact Further development of IP is ongoing
 
Title Investigation of Levetiracetam in Alzheimer's Disease (The ILiAD Trial); a proof of concept study - Arjune Sen Project 
Description Unique proof of concept, randomised, double blind, placebo controlled cross-over trial using Levetiracetam, a medicine used to treat epilepsy, in Alzheimer's Disease. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2020
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Testing of licensed drug in another indication 
URL https://www.nhs.uk/medicines/levetiracetam/
 
Company Name BLUE WATER VACCINES INC. 
Description A company developing a universal flu vaccine based on technology developed at the University of Oxford 
Year Established 2019 
Impact Vaccine development & clinical trials
Website https://www.bluewatervaccines.com/
 
Company Name GYREOX LIMITED 
Description GyreOx is a privately-held biotechnology company, based on the Harwell Campus, Oxfordshire, UK. The Company is focussed on creating novel medicines addressing complex intra-cellular targets in a wide range of diseases. Its proprietary platform technology is based on a combination of chemistry and synthetic biology deploying a set of rationally engineered enzymes. 
Year Established 2019 
Impact We have created a chemoenzymatic technology for macrocycle generation. The technology consists of a set of flexible engineered enzymes which can carry out modification steps on a synthetic linear substrate to generate modified macrocycles.
Website https://www.gyreox.com/
 
Company Name Lime Biosciences Ltd 
Description Research and experimental development on biotechnology and DNA assembly 
Year Established 2019 
Impact None yet
 
Description British Neuroscience Association 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Presented research in the form of a talk. Scientific Meeting.
Year(s) Of Engagement Activity 2019
URL https://meetings.bna.org.uk/bna2019/
 
Description International Oligonucleotides and Peptides Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Academic and Industry partner meeting for development of Oligo and Peptide technologies
Year(s) Of Engagement Activity 2019
URL https://www.iopc-tks.com/past-edition/
 
Description International workshop in CLL in Edinburgh - Anna Schuh Project 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Programme Committee co-chair for the international workshop in CLL in Edinburgh (2000 delegates); PI Anna Schuh introduced a new session on "global CLL" with invited speakers from all continents
Year(s) Of Engagement Activity 2019
URL https://www.iwcll2019.org/
 
Description Oligonucleotide Therapeutic Society 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presented work in the form of a talk.
Year(s) Of Engagement Activity 2019
URL https://www.oligotherapeutics.org/2018-annual-meeting/
 
Description Oligonucleotide Therapeutic Society 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presented new research
Year(s) Of Engagement Activity 2019
URL https://www.oligotherapeutics.org/2019-annual-meeting/
 
Description Presentation to Tanzanian Minister of Health - Anna Schuh Project 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Presentation to Tanzanian Minister of Health during the AORTIC meeting in Mozambique in 2019. Presentation has potential to influence health policy across Tanzania
Year(s) Of Engagement Activity 2019
 
Description Talk - SMA Europe 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Scientific research talk to disseminate the work generated and increase awarness.
Year(s) Of Engagement Activity 2020
URL https://www.sma-europe.eu/our-projects/our-congresses/congress-2020/